
- ONCOLOGY Vol 23 No 7
- Volume 23
- Issue 7
FDA Fast-Tracks Talactoferrin/Sunitinib for Renal Cell Carcinoma
Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent).
Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent). The Fast Track program is designed to expedite the review of investigational drugs for the treatment of patients with serious or life-threatening diseases where there is an unmet medical need.
Articles in this issue
almost 17 years ago
Low-Risk Papillary Thyroid Cancer: Treatment Options and Patient Perceptionsalmost 17 years ago
Prophylactic Central Lymph Node Dissection: Continued Controversyalmost 17 years ago
Music Therapyalmost 17 years ago
Is There a Role for LHRH Antagonists in Prostate Cancer?almost 17 years ago
Important Considerations in LHRH Antagonist Therapy for Prostate Canceralmost 17 years ago
The Role of LHRH Antagonists in the Treatment of Prostate CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































